OBJECTIVES: To evaluate the cost-effectiveness of continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) in type 1 diabetes mellitus (T1DM) in adults in the Russian Federation

METHODS: A Markov model with 15 year time horizon with 1 year cycle duration was used. To calculate QALY for the entire simulation period, the utility weights for each condition in which the patient arrives during a certain period were used. Utility weights and number of complications were found in published literature. Direct costs included the cost of correcting the complications of T1DM, insulin pump, the ultrashort insulin and long-acting insulin pens, infusion sets, reservoirs. Indirect costs included: loss of gross domestic product due to premature mortality, disability pension. Discount rate 5%. The exchange rate used USD 1 = 66 RUB.

RESULTS: The use of therapy with CSII resulted in a higher QALY value of 9.45 years compared with MDI 8.70 years. The total costs of during CSII treatment for one average patient was USD 2 456 per year, during MDI treatment USD 1 838 per year. The CER of CSII was USD 3 901, MDI was USD 3 169. The ICER was USD 7 981/QALY, below the recognised willingness to pay threshold of USD 25 227.

CONCLUSIONS: This analysis demonstrated therapy with CSII compared MDI is characterized by higher clinical efficacy and is a cost-effectiveness in the Russian Federation.